North Carolina Headlines

DelveInsight, a leading market research and healthcare consulting firm, has released its latest report, “Fibromyalgia Market Insights, Epidemiology, and Market Forecast–2036.” The report provides a comprehensive analysis of Fibromyalgia epidemiology, evolving treatment paradigms, market dynamics, competitive landscape, and forecasted Fibromyalgia Market Size across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways from the Fibromyalgia Market Report

• The Fibromyalgia Market Size in the 7MM is anticipated to expand significantly during the forecast period 2022–2036.

• DelveInsight estimates that the Fibromyalgia Market Size across the seven major markets is expected to increase from approximately USD 3.7 billion in 2022 to nearly USD 5.9 billion by 2036.

• The United States accounted for the largest Fibromyalgia Market Share among the 7MM in 2025 and is expected to maintain its dominance throughout the forecast period.

• According to secondary research, fibromyalgia affects approximately 2–3% of the population in the United States and several other countries, highlighting a considerable patient burden worldwide.

• Fibromyalgia is estimated to affect approximately 1.8–2.9 million individuals in the United Kingdom, with women being diagnosed considerably more frequently than men.

• In Japan, fibromyalgia affects approximately 2.1% of adults, with women accounting for the majority of diagnosed cases.

• Spain reports an estimated fibromyalgia prevalence of 2.45%, while prevalence in Italy is generally estimated at 2–3% in the general population and exceeds 20% among certain high-risk patient groups.

• In August 2025, Tonix Pharmaceuticals received US FDA approval for TONMYA (cyclobenzaprine HCl sublingual tablets), marking the first newly approved Fibromyalgia Drug in over 15 years.

• Leading Fibromyalgia companies, including Tonix Pharmaceuticals and Ono Pharmaceutical, are actively working to advance innovative treatment options that may transform the future Fibromyalgia Drug Market.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/fibromyalgia-market

Key Factors Driving the Fibromyalgia Market

Increasing Disease Burden and Patient Awareness

Growing recognition of fibromyalgia as a chronic pain disorder, coupled with improved awareness among healthcare professionals and patients, is supporting earlier diagnosis and treatment initiation. The rising prevalence of chronic pain syndromes continues to expand the Fibromyalgia Patient Pool and drive demand within the Fibromyalgia Market.

Advancements in Fibromyalgia Treatment Approaches

The Fibromyalgia Treatment Market is benefiting from the adoption of comprehensive, multimodal treatment strategies that combine pharmacological and non-pharmacological interventions. Increasing utilization of cognitive behavioral therapy (CBT), exercise-based therapies, mindfulness programs, and individualized treatment plans is improving disease management outcomes.

Expansion of the Fibromyalgia Drug Market

Pharmacological management remains a critical component of fibromyalgia care. Commonly used therapies include SNRIs such as duloxetine and milnacipran, α-2 ligands including pregabalin and gabapentin, and tricyclic antidepressants. The approval of TONMYA and the emergence of pipeline assets are expected to create new opportunities in the Fibromyalgia Drug Market and strengthen future Fibromyalgia Market Trends.

Fibromyalgia Market Trends and Competitive Landscape

The Fibromyalgia Industry is witnessing renewed innovation following years of limited therapeutic advancement. The approval of TONMYA has revitalized interest in the Fibromyalgia Treatment Market, while emerging therapies continue to attract industry attention.

Among the most promising Fibromyalgia Drugs in development is:

• TONMYA (cyclobenzaprine hydrochloride sublingual tablets) – Tonix Pharmaceuticals

• ONO-1110 – Ono Pharmaceutical

TONMYA demonstrated meaningful pain reduction in Phase III studies and became the first newly approved fibromyalgia therapy in more than 15 years. Meanwhile, ONO-1110 is being evaluated as an investigational oral therapy designed to modulate the endocannabinoid system, potentially addressing pain pathways and central sensitization associated with fibromyalgia.

These innovations are expected to contribute significantly to Fibromyalgia Market Share expansion and strengthen long-term Fibromyalgia Market Growth.

Discover more about therapies set to grab major Fibromyalgia Market share @ Fibromyalgia Treatment Landscape

Recent Developments in the Fibromyalgia Industry

• In August 2025, Tonix Pharmaceuticals announced that the US FDA approved TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults.

• ONO-1110, developed by Ono Pharmaceutical, is currently being investigated in a Phase IIa randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating efficacy and safety in adult patients with fibromyalgia. Approximately 160 patients are expected to be enrolled in the study.

What is Fibromyalgia?

Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive dysfunction, and emotional symptoms such as anxiety and depression. The condition significantly affects quality of life and daily functioning. Although fibromyalgia can affect individuals of all ages and genders, it is most commonly diagnosed in women and typically develops during adulthood.

Fibromyalgia Epidemiology Segmentation

The Fibromyalgia epidemiology analysis provides historical and forecasted patient population trends across the 7MM and includes:

• Total Prevalent Cases of Fibromyalgia

• Total Diagnosed Prevalent Cases of Fibromyalgia

• Gender-specific Cases of Fibromyalgia

• Severity-specific Cases of Fibromyalgia

• Total Treated Cases of Fibromyalgia

Scope of the Fibromyalgia Market Report

• Comprehensive assessment of current and emerging Fibromyalgia therapies

• Detailed Fibromyalgia Market Size analysis across the 7MM

• Evaluation of Fibromyalgia Market Trends and future growth opportunities

• Epidemiology-based market forecasting from 2022–2036

• Competitive intelligence and SWOT analysis

• Market access and reimbursement assessment

• Key company profiles and pipeline analysis

• Expert insights, analyst perspectives, and unmet needs evaluation

To know more about Fibromyalgia companies working in the treatment market, visit @ Fibromyalgia Clinical Trials and Therapeutic Assessment

Table of Contents

• Fibromyalgia Market Report Introduction

• Executive Summary of Fibromyalgia Market

• SWOT Analysis of Fibromyalgia

• Fibromyalgia Epidemiology and Patient Population

• Fibromyalgia Market Overview

• Current Fibromyalgia Treatment Landscape

• Fibromyalgia Emerging Therapies

• Fibromyalgia Drug Market Analysis

• Fibromyalgia Market Trends

• Fibromyalgia Market Size and Forecast (2022–2036)

• Country-wise Fibromyalgia Market Analysis

• Market Access and Reimbursement

• Market Drivers and Barriers

• Competitive Landscape

• Analyst Views and KOL Insights

• Appendix

• Report Methodology

• About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/